WHO Launches Groundbreaking Online Repository for Evidence-Informed Decision-Making Tools

By HEOR Staff Writer

September 19, 2023

Evidence-Informed Decision-Making

The World Health Organization (WHO) has launched an innovative online repository of Evidence-Informed Decision-Making (EIDM) tools. This pioneering platform, the first of its kind, showcases WHO tools and external tools used by WHO to facilitate knowledge translation. It also highlights partner organisations involved in planning, managing, monitoring, and evaluating the process of evidence use and implementation.

Developed by the Evidence to Policy and Impact Unit of the Research for Health Department in the Science Division, in collaboration with the Evidence-Informed Policy Network (EVIPNet), the repository supports the unit’s EIDM capacity-sharing work. The platform complements the WHO evidence ecosystem framework published last year, specifically focusing on the policy/action cycle.

Navigating the Online Platform

The user-friendly online platform enables users to search and access EIDM methods and tools corresponding to each step of the policy/action cycle. Users can refine their searches using advanced functionalities to filter by document type, language, and publication date. The platform offers tools that span the clinical (or practice), public health, and health system domains.

Currently, the repository houses and maintains 75 tools, with continuous updates as new tools emerge. The Evidence to Policy and Impact Unit plans to actively add more tools to the repository, employing a scoping literature review and other steps.

The ultimate goal of EIDM and the work of EVIPNet is to support WHO staff and Member States in applying rigorous, systematic, and transparent methods for the creation and application of research evidence in their day-to-day work. This will enable the organisation to successfully achieve the “Triple Billion” targets: a billion more people with universal health coverage, a billion more people protected from health emergencies, and a billion more people with better health and well-being.

Reference url

Recent Posts

delpacibart braxlosiran FSHD
Delpacibart Braxlosiran FSHD Shows Promise in Disease Modification

By João L. Carapinha

June 11, 2026

Novartis has achieved a key clinical milestone with delpacibart braxlosiran FSHD, as its FORTITUDE biomarker cohort successfully met the primary endpoint by substantially suppressing DUX4-driven gene expression and reducing muscle damage markers in patients with facioscapulohumeral muscular dystr...
athlete risk stratification
Advancing Athlete Risk Stratification with Predictive Frameworks

By João L. Carapinha

June 11, 2026

Athlete risk stratification now integrates epidemiological evidence, explainable artificial intelligence, and mechanistic cardiac models to better protect young competitors. This convergence offers a path to distinguish healthy athletic remodeling from hidden substrates that can trigger fatal arr...
Innovative Therapies Access Portugal
Evaluating Innovative Therapies Access in Portugal

By João L. Carapinha

June 11, 2026

According to Paulo Gonçalves in the APIFARMA newsletter, Innovative Therapies Access in Portugal directs resources toward therapeutic innovation at levels substantially below feasible ambitions. Protracted authorization processes impose measurab...